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Objective: To evaluate nosocomial accounts of 426
extended spectrum b-lactamase (ESBL)-producing strains
from 705 isolates of 9 pathogenic gram-negative bacteria
in vitro. We analysed the genetic divergence of ESBLs by
constructing a phylogenetic tree and modelled flavonoid
inhibition of ESBLs with in silico molecular docking to
determine effective control options.
Methods: Nine ESBL-producing bacteria were isolated
from urine samples and their antibiograms were deter-
mined by the disc-diffusion method. Comparative models
of the 9 ESBL enzymes were generated computationally
using reference sequences, and validated by Ramachan-
dran plots. Molecular docking with 11 flavonoids was
conducted against the ESBL models.
Results: Isolated strains were floridly multidrug-resistant.
From the docking study, the predicted minimum energy
value of amikacin was 8.108 kcal/mol against the wild
type TEM-1 ESBL of Acinetobacter baumannii, while the
docking value against the mutant type Escherichia coli
was 7.388 kcal/mol. The docking scores obtained
corroborated the in vitro results showing that the antibi-
otic was incapable of controlling the ESBL of the mutant
strain. Among 11 flavonoids tested against the mutant
ESBL of E. coli, epigallocatechin 3-gallate and erio-
dictyol, with docking scores of 9.448 and 8.161 kcal/
mol, respectively, were the most effective, with drug-
likeness scores of 0.39 and 1.37, respectively, compared
to 1.03 for amikacin.
Conclusion: Docking scores and drug-likeness scores
indicated that flavonoids are compelling alternative
antimicrobial agents that could serve as complementary
therapy for newly arising ESBL-producing bacteria.his is an open access article under the CC BY-NC-ND license
16/j.jtumed.2016.03.007
S.S. Swain and R.N. Padhy218Phylogenetic tree analysis elucidated the genetic rela-
tionship of the 9 ESBL serotypes.
Keywords: Comparative modelling; ESBL enzymes;
Flavonoids; Gram-negative bacteria; Molecular docking
 2016 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Sir Alexander Fleming discovered the first antibiotic,
penicillin with a b-lactam ring, in 1927. With reports of
bacterial resistance to penicillin beginning around the 1940s,
several chemical derivatives of penicillin have since been
developed. These derivatives are extended spectrum b-lac-
tams that include penems, cephalosporins (cephems), mon-
obactams, and carbapenems. In the last 60 years, the b-
lactam class of antibiotics constitutes approximately 60% of
all antibiotics used in human and veterinary medicine to
combat gram-negative bacteria.1e3 The mechanism by which
b-lactams can kill bacteria is by thwarting cell-wall synthesis.
However, bacteria can survive by hydrolysing the b-lactam
ring with the enzyme b-lactamase, which continually evolves,
and eventually even the next generation cephalosporins,
carbapenems and monobactams can be inactivated. Conse-
quently, a spectrum of enzymes known as extended spectrum
b-lactamases (ESBLs) were identified around the 1980s in
gram-negative (GN) rods.4,5 ESBLs are harboured on
plasmids that are easily transmitted/transferred to other
bacteria. Over time, bacterial resistance to the b-lactam
group has led to the development of different antibiotics
such as aminoglycosides and fluoroquinolones, which have
inhibitory actions on bacterial proteins or DNA synthesis.
Resistance also evolves simultaneously and independently
to these classes of antibiotics in most bacteria, so that most
bacteria are multidrug-resistant (MDR).3 In spite of this,
antibiotics of these classes are often used.
As increased hospitalization costs, morbidity, and pro-
portionate mortality have been recorded,8,9 several
guidelines have been published for the control of
nosocomial infections due to antibiotic-resistant bacteria.6,7
The example of insurmountable challenges from
methicillin-resistant Staphylococcus aureus (MRSA), as
recorded from this hospital,9 is universally reported.10,11 The
situation has gone from bad to worse with only a few
pathogens, including the isolation of an antibiotic-resistant
strain of the GN bacterium, Klebsiella pneumoniae, which
has caused the fatality of a neonate in this hospital.12
Indeed, effective control of antibiotic-resistant bacteria,
particularly the ESBL-producing cohort of GN bacteria,
needs to be studied in detail because evolution in bacterial
species are known to occur in a Darwinian way.9 The
nosocomial infection of patients in hospitals is due to
continual amplification of reservoirs of antibiotic-resistant
bacteria in healthcare settings. The use of a drug/antibi-
otic induces resistance to that particular drug in the targetbacteria or other member(s) of the same class, which might
harbour inducible resistance genes. When a patient is
treated with an antibiotic, it eliminates the majority of
bacteria, but a minor fraction, or even one cell, with an
altered genetic makeup survives, arising from mutation or
acquired from well-known genetic recombination methods.
Survival and predominance of the fittest bacterium even-
tually spreads in the hospital as antibiotic-resistant strains.
The transmission of plasmid-encoded bacterial genes allows
the resistance genes to migrate to phylogenetically distant
bacteria.13
From this perspective, development of antimicrobials
derived from natural sources has been suggested in litera-
ture.14,15 The use of crude extracts of plants, with a history of
ethnomedicinal use, would be a suitable approach. Any
drug-resistant microbe should not be able to survive the
combined use of the plant extract with traditional antibiotics,
especially in critical patients where multiple antibiotics are
needed.
The present work describes nosocomial accounts of 9
ESBL-producing GN bacteria, isolated from urine samples
over the course of one year in a hospital, regardless of
whether the patients were suffering from urinary tract
infection. Their antibiograms to commonly used antibiotics
were determined. A phylogenetic tree was constructed using
published reference sequences of these bacteria. Protein 3-D
structures of the 9 ESBLs, including a sensitive temoneira-1
(TEM-1) ESBL variant, were generated by homology
modelling and validated by Ramachandran plots. Addi-
tionally, 11 flavonoids were used in molecular docking
against the modelled Acinetobacter baumannii ESBL protein
and the TEM-1mutant of E. coli obtained from Protein Data
Bank (PDB).
Materials and Methods
Isolation and identification of pathogenic bacteria
A total of 1250 urine samples were collected from patients
admitted to inpatient (wards, cabins and ICUs) and
attending outpatient department (OPD) units of the hospital.
The samples yielded 705 strains of pathogenic GN bacteria
belonging to 9 bacterial species, during the span of 12 months
(January to December 2013). All isolated bacterial strains
were assigned to A. baumannii, Citrobacter sp., E. coli,
Enterobacter aerogenes, Klebsiella oxytoca, K. pneumoniae,
Proteus mirabilis, Proteus vulgaris, and Pseudomonas aeru-
ginosa using standard biochemical tests (oxidase test, indole
test, methyl red (MR) test, VogeseProskauer test, citrate
test, urease test, triple-sugar-iron test and nitrate test) and
were maintained as axenic cultures in suitable media, as
previously described.9,16
Antibiotic susceptibility test
All isolated bacterial strains, including the standard Mi-
crobial Type Culture Collection strains of each bacterium,
were subjected to antibiotic sensitivity tests by the Kirbye
Bauer’s method, using 4 mm thick MuellereHinton (MH)
agar (HiMedia, Mumbai) medium, with 8 high-potency
antibiotic discs (HiMedia) of 15 prescribed antibiotics
Table 1: Bacteria isolated from urine samples from Januarye
December 2013 in each four month period (phases, I, II and
III).
Bacteria Phase I Phase II Phase III Total
CA HA CA HA CA HA
Acinetobacter baumannii 17 11 11 09 12 15 75
Citrobacter freundii 10 02 05 08 04 09 38
Enterobacter aerogenes 11 07 03 04 13 06 44
Escherichia coli 35 47 38 29 39 47 235
Klebsiella oxytoca 03 0 05 01 0 04 13
Klebsiella pneumoniae 26 21 23 28 25 16 139
Proteus mirabilis 07 03 e 08 11 07 36
Proteus vulgaris 02 01 03 01 06 04 17
Pseudomonas aeruginosa 21 14 17 18 15 23 108
Grand total 132 106 123 106 125 131 705
HA, hospital acquired; CA, community acquired.
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susceptibility-test chart of Clinical Laboratory Standard
Institute (CLSI) guidelines.16,17
Computational study
ESBL-producing reference sequences of the 9 GN species
were retrieved from UniprotKB sequence database.
Comparative modelling was performed with MODELLER
9.10. The modelled protein was validated by PROCHECK,
Ramachandran plot analysis, WHAT IF, MolProbity and
ProSA-web. The energyminimization of the resulting protein
model was performed by Swiss-PDB Viewer software (http://
spdbv.vital-it.ch/). Protein folding illustrations and protein-
ligand(s) interactions were carried out using Discovery Stu-
dio Visualizer 4.0 (http://accelrys.com/) and PyMOL (http://
www.pymol.org/). The molecular protein-ligand(s) docking
was performed by AutoDock Vina software.18,19
Comparative modelling and validation
A. baumannii TEM-1 and the 8 other ESBL protein se-
quences were subjected to BLASTp searches. Based on the
high level of identity between the target sequence and the
template structure, it was found that the “TEM-1 b-lacta-
mase X-ray diffraction 3-D structure of E. coli” (PDB with
ID: 1ZG4) at the 1.5 A˚ resolution, was the best template for
A. baumannii TEM-1. After selecting the most appropriate
template for each bacterial sequence, the MODELLER and
Swiss-model software were used for homology modelling.
Next, Swiss-PDB Viewer was implemented for energy mini-
mization. The refined model was validated with both PRO-
CHECK and Rampage to confirm that all bond lengths,
dihedral angles and torsion angles attained a stable
configuration.
Phylogenetic tree analysis
The analysis of phylogenetic relationships is a computa-
tional process for comparison of different variants of same or
different families of genes, through a phylogenetic tree. A
phylogenetic tree helps to find new or recently evolved var-
iants, if any, by multiple sequence alignments of individual
genomic or protein sequences. Phylogenetic trees are con-
structed by computational programs using different algo-
rithms. Here, the phylogenetic relationships of the 9
reference ESBL protein sequences were calculated by Clus-
talW2 and Mega 6.06 software.
Molecular docking study
Molecular docking is a computational attempt to estimate
the minimum energy generated between desired target pro-
tein and each ligand, individually. The druggable target
protein is the larger molecule related to a particular pheno-
type and the ligand is the smaller natural or synthetic
chemical that is the candidate drug, by which the activity of
the target molecule is blocked after binding to the active site.
The effective ligand against a targeted protein is selected by
the minimum docking score between protein-ligand in-
teractions. Here, 11 flavonoids were used as ligands againsttwo target proteins: one was generated by homology
modelling and other was retrieved from PDB. The first target
protein, wild type TEM-1 of A. baumannii and the second
target protein, a mutant TEM-12 from E. coli (PDB ID:
1ESU), were subjected to docking analysis. Moreover, the
controlling capacities of 11 individual flavonoids were pre-
dicted against wild type and mutant TEM variant proteins,
with the antibiotic amikacin used as the reference.
Results
Isolation and identification of pathogenic bacteria
We isolated 705 strains of 9 species of GN bacteria, with
numbers as specified: 75 strains of A. baumannii, 38 strains of
Citrobacter sp., 44 strains of E. aerogenes, 235 strains of
E. coli, 139 strains ofK. pneumoniae, 13 strains ofK. oxytoca,
36 strains of P. mirabilis, 17 strains of P. vulgaris, and 108
strains of P. aeruginosa. Thus, E. coliwas the most frequently
isolated species, followed by K. pneumoniae, P. aeruginosa,
A. baumannii, E. aerogenes, P. mirabilis, P. vulgaris and
K. oxytoca (Table 1).
A. baumannii was identified by colony characteristics on
nutrient agar (NA), MacConkey (MC) agar, cysteine-
lactose-electrolyte-deficient (CLED) agar, and with results
obtained from adopted biochemical procedures: it grew as
colourless, smooth, opaque, raised-pinpoint colonies on NA
and as non-lactose-fermenting (NLF) colonies on MC agar;
it was positive for catalase, VogeseProskauer (VP), and
citrate tests; and it was negative for oxidase, indole, MR and
nitrate tests. The other bacterial isolates were similarly
identified.
Antibiotic susceptibility tests
Among the b-lactams, the average percent resistance to
amoxyclav (30 mg/disc) were: A. baumannii, 50; Citrobacter
freundii, 25.7; E. aerogenes, 52.7; E. coli, 77; K. oxytoca, 61;
K. pneumoniae, 31; P. mirabilis, 38.3; P. vulgaris, 33.3; and
P. aeruginosa, 65.3. The average percent of resistance to
ampicillin (10 mg/disc) were: A. baumannii, 71.7; C. freundii,
58.3; E. aerogenes, 69.7; E. coli, 70.3; K. oxytoca, 78;
Table 2: Percent resistance of bacterial isolates to b-lactam and cephalosporin antibiotics (mg/disc).
Bacteria b-lactams Cephalosporins
Amoxyclav 30 Ampicillin 10 P/T 100/10 Cefepime 30 Ceftazidime 30 Ceftriaxone 30
I II III I II III I II III I II III I II III I II III
A. baumannii 47 52 51 69 77 69 62 67 74 50 56 62 69 77 69 52 55 59
C. freundii 25 24 28 54 59 62 56 54 56 37 38 38 54 59 62 27 34 41
E. aerogenes 45 52 61 65 69 75 52 61 63 72 77 79 65 69 75 52 57 53
E. coli 72 78 81 62 71 78 74 78 79 75 80 82 62 71 78 79 79 78
K. oxytoca 55 61 67 74 79 81 51 59 62 71 72 75 74 79 81 66 78 77
K. pneumoniae 27 31 35 74 79 83 60 68 72 32 39 42 74 79 83 54 59 63
P. mirabilis 34 39 42 32 41 43 31 45 47 27 31 34 32 41 43 34 43 45
P. vulgaris 25 34 41 34 39 48 35 37 43 38 46 47 34 39 48 36 41 43
P. aeruginosa 56 69 71 55 54 67 79 81 78 67 76 82 55 54 67 49 61 68
Table 3: Percent resistance of bacterial isolates to amino-
glycoside antibiotics (mg/disc).
Bacteria Aminoglycosides
Amikacin 30 Gentamicin 10 Tobramycin 10
I II III I II III I II III
A. baumannii 33 41 48 62 67 74 47 56 62
C. freundii 23 27 34 56 54 56 48 51 58
E. aerogenes 36 39 45 52 61 63 55 61 66
E. coli 68 71 78 74 78 79 82 84 90
K. oxytoca 66 69 73 51 59 62 75 79 81
K. pneumoniae 47 49 52 60 68 72 71 75 81
P. mirabilis 37 34 35 31 45 47 27 32 38
P. vulgaris 34 43 45 35 37 43 31 38 44
P. aeruginosa 75 77 83 79 81 78 64 69 77
Table 5: Percent resistance of bacterial isolates to stand-alone
antibiotics (mg/disc).
Bacteria Stand-alones
Co-trimoxazole 25 Nitrofurantoin 300
I II III I II III
A. baumannii 58 63 68 42 48 53
C. freundii 45 52 57 37 41 44
E. aerogenes 51 59 62 38 42 56
E. coli 62 70 72 65 70 76
K. oxytoca 75 82 88 61 67 78
K. pneumoniae 43 51 53 75 82 87
P. mirabilis 64 65 71 29 35 40
P. vulgaris 35 32 36 32 41 52
P. aeruginosa 45 38 44 38 42 49
S.S. Swain and R.N. Padhy220K. pneumoniae, 78.7; P. mirabilis, 38.7; P. vulgaris, 40.3; and
P. aeruginosa, 58.7. Finally, the average percent of resistance to
piperacillin/tazobactam (100/10 mg/disc) were: A. baumannii,
67.7;C. freundii, 55.3;E. aerogenes, 58.7;E. coli, 77;K.oxytoca,
57.3;K. pneumoniae, 66.7;P.mirabilis, 41;P. vulgaris, 38.3; and
P. aeruginosa, 79.3 (Table 2). Similarly, resistance patterns to
cephalosporins (Table 2), aminoglycosides (Table 3),
fluoroquinolones (Table 4) and stand-alone antibiotics
(Table 5) were recorded.Table 4: Percent resistance of bacterial isolates to fluoroquinolone a
Bacteria Fluoroquinolones
Gatifloxacin 5 Levofloxacin 5
I II III I II
A. baumannii 62 67 74 55 64
C. freundii 56 54 56 27 35
E. aerogenes 52 61 63 54 59
E. coli 74 78 79 55 67
K. oxytoca 51 59 62 66 69
K. pneumoniae 60 68 72 33 35
P. mirabilis 31 45 47 27 31
P. vulgaris 35 37 43 25 32
P. aeruginosa 79 81 78 63 68Discussion
It was evident that currently or commonly used antibi-
otics were ineffective against a number of the bacterial iso-
lates. Antibacterial resistance has arisen due to rapid changes
in bacterial biochemical levels, target modification, target
group bypass and alterations in efflux pumps, due to genetic
alterations (e.g., mutation and horizontal gene transfer).
ESBLs are inhibited by antibiotics and b-lactamasentibiotics (mg/disc).
Ciprofloxacin 5 Ofloxacin 5
III I II III I II III
67 38 42 49 52 55 61
39 29 35 40 47 52 51
62 32 41 52 52 57 63
71 58 62 69 79 79 88
78 54 67 71 59 61 65
42 35 41 47 54 59 63
35 27 31 35 34 43 45
39 34 39 42 36 41 43
72 75 79 81 49 61 68
Figure 1: Classification of b-lactamase and ESBL genes. Class A and D genes are responsible for antibiotic resistance by hydrolysing the
b-lactam ring.
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eventually the bacteria are controlled. However, ESBL genes
are transmissible between bacteria and remain peripatetic,
mainly among gram-negatives.20,21
b-lactamases are broadly categorized into two types,
serine b-lactamases and metallo-b-lactamases. In the former,
there are three proposed classes, class A, C and D.22,23
Among these, class A consists of TEM and sulfhydryl
variable (SHV) variants of ESBLs with corresponding
resistances, while class D consists of cloxacillin and
oxacillin (OXA) variants. Classes A and D constitute all
detected variants of ESBLs, whereas class C consists of a
non-ESBL variant commonly isolated from extended-
spectrum cephalosporin-resistant GN bacteria with AmpC
(Figure 1, Table 1).Figure 2: Sequence-structure alignment of the query and template. Th
structure of 1ZG4 (template) was performed.The OXA-type b-lactamase emerged with a narrow
spectrum in the co-evolution with TEM and SHV,24
occurring predominantly in P. aeruginosa strains.25 The
other types of ESBLs, cefotaximase-Munich (CTX-M),
Pseudomonas Extended resistance (PER-1), Brazilian
Extended Spectrum b-lactamase (BES-1), Chryseobacterium
meninggosepticum (CME-1), Vietnamese Extended Spectrum
b-lactamase (VEB-1) and Serratia fonticola (SFO-1), TLA,
and a Mexican group (TLA-1) have been described in detail
elsewhere.26 The Guyana Extended-Spectrum b-lactamases
(GES) belonging to class A have hydrolysing activity against
penicillin and extended-spectrum cephalosporins but are
sensitive to general inhibitors of b-lactamase.27 These types
of ESBL variants have evolved mainly with genetic changes
from TEM and SHV sub-types, and bear 25e27%e alignment of the A. baumannii TEM-1 sequence (query) with the
Table 6: Retrieved b -lactamase protein sequences of 9 bacterial ESBLs and their 3-D protein structures by homology modelling.
Retrieved b -lactamase protein sequence Generated 3D structure
>Q6WZD4jBeta-lactamase OS¼Acinetobacter baumannii GN ¼ blaTEM-1
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW
>Q7B3X5jBeta-lactamase OS¼Citrobacter freundii GN ¼ blaTEM1
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW
>Q6W7F6jBeta-lactamase OS ¼ Enterobacter aerogenes GN ¼ blaTEM-121
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDKLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVKYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGTGKRGS
SGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW
>P62593jBeta-lactamase TEM OS¼Escherichia coli GN ¼ bla
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW
>Q48406jBeta-lactamase TEM-12 OS¼Klebsiella oxytoca GN ¼ blaT-12b
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW
>I7ANY8jBeta-lactamase OS¼Klebsiella pneumoniae GN ¼ TEM-1
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIXLDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAXXXXSLIKHW
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Table 6 (continued )
Retrieved b -lactamase protein sequence Generated 3D structure
>B9DR46jBeta-lactamase OS¼Proteus mirabilis GN ¼ blaTEM
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNIGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW
>B3VI32jBeta-lactamase OS¼Proteus vulgaris PE ¼ 3 SV ¼ 1
MNVIIKAVVTASTLLMVSFSSFETSAQSPLLKEQIESIVIGKKATVGVAVWGPDDLEPLL
INPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTWAPIMKAYQGDEF
SVPVQQLLQYSVSHTDNVACDLLFELVGGPAALHDYIQSMGIKETAVVANEAQMHADDQV
QYQNWTSMKGAAEILKKFEQKTQLSETSQALLWKWMVETTTGPERLKGLLPAGTVVAHKT
GTSGIKAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNEAIIAQVAQTAYQFELK
KLSALSPN
>Q6LBN9jBeta-lactamase OS¼Pseudomonas aeruginosa GN ¼ blatem-1A
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW
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these variants of ESBLs have a unique characteristics,
individually and in different bacterial species.Computational analyses
The ESBL protein models of were generated by the ho-
mology modelling protocol. The sequence-structure ofFigure 3: Ribbon representation of A. baumannii TEM-1 protein
3-D structure by PyMOL software.A. baumannii TEM-1 was aligned with the structure of E. coli
TEM-1 (PDB ID: 1ZG4) (Figure 2). Similarly, for of the
remaining ESBLs, alignments were performed between
template structures with individually retrieved target
sequences (Table 6). After modelling of A. baumannii TEM-
1, a 3-D structure was created (Figure 3), which was
analysed by Ramachandran plot analysis and the
PROCHECK program (Figure 4 and Figure S1). It was
found that the phiepsi angles of 97.5% of the residues were
in the most favoured regions, while 2.5% residues were in
additional allowed regions, but no residues fell in the
disallowed regions (Figure 4), confirming the reliability of
the modelled structure. Unavailable in PDB, the generated
model was used as a target herein, concomitantly that it
would lend itself to future antibacterial drug development
efforts.
Phylogenetic trees were constructed though the
maximum likelihood method (Figure 5). ClustalW2 was
used for multiple sequence alignments among ESBL
reference sequences. The constructed phylogenetic tree
presents the genetic distance of the 9 ESBL variants. For
example, between the reference sequence of SHV-11 and
that of blaSHV-12 of E. coli, the alignment showed the
amino acid residues at positions at 234 and 235 positions
were different (Figure S4). Furthermore, multiple sequence
alignments of 3 variants of K. pneumoniae, blaSHV-40,
blaSHV-41 and blaSHV-42 have changes at amino acid
positions that probably occurred over several generations.
Figure 4: Ramachandran plot of A. baumannii TEM-1 model. The graph was created with the Ramachandran plot analysis program, with
97.5% of the amino acids in the favoured region, 2.5% in the allowed region, and none in the outlier region.
S.S. Swain and R.N. Padhy224Such mutations directly affect the antibiotic resistance30e32
(Figure S5).
The phylogenetic trees were in accordance with noso-
comial data that the main cause of antibiotic resistanceFigure 5: Phylogenetic tree of 9 species of bacteria based on reference
using the ClustalW2 and MEGA 6.06 software; A and B are two diffwas due to modifications of bacterial genomes. Therefore,
we performed molecular docking studies of flavonoids
against two ESBLs, a wild type and a mutant target.
The docking score with amikacin as the ligandESBL sequences retrieved from UniprotKB database constructed
erent views of the phylogenetic tree.
Figure 6: A, Three-dimensional structure of the protein-ligand interaction of epigallocatechin 3-gallate with the target surface of the
E. coli TEM-1 mutant model (PDB ID: 1ESU); B, Structure of the same protein-ligand, amino acids of the target protein interacting with
the ligand epigallocatechin 3-gallate were predicted with the Discovery studio Visualizer 3.1 software.
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A. baumannii, while the docking score against the mutant
E. coli type was 7.388 kcal/mol. The docking scores
predicted that amikacin would be ineffective for control-
ling the mutant strain in comparison to the wild type
bacterial strain (Figure 6).
Drug-likeness scores of individual flavonoids and
amikacin were calculated using Molsoft (http://molsoft.
com/mprop/), to predict the effectiveness as an inhibi-
tor. The decreasing orders of flavonoids with drug-
likeness scores were: eriodictyol (1.37) > naringenin
(1.13) > quercetin (0.93) > catechin (0.92) > hesperetin
(0.88) > luteolin (0.86) > apigenin and kaempferol
(0.77) > isorhamnetin (0.67) > epigallocatechin 3-gallate
(0.39) > theaflavin (0.31), and the drug-likeness score of
amikacin was 1.03, based on canonical simplified
molecular-input line-entry system (SMILES) of each
chemical using Molsoft (Table 7). The drug-likeness score
of each individual flavonoid indicated their suitability for
consideration as a drug. The 11 flavonoids were individ-
ually docked against the same wild type target of TEM-1
and mutant TEM-12. A minimum (more negative) bind-
ing affinity or docking score (or energy value) in protein-
ligand interactions indicates a more effective chemical
compound. The docking scores of 11 flavonoids against
of the wild type A. baumannii are listed in decreasing
order: epigallocatechin 3-gallate (9.665) > naringenin
(9.658) > catechin (8.870) > hesperetin (8.456)
> eriodictyol (8.432) > apigenin (8.245) > luteolin
(8.226) > kaempferol (8.219) > quercetin (8.209)
> theaflavin (7.989) > isorhamnetin (7.809). By
comparison the values against the E. coli mutant were:
epigallocatechin 3-gallate (9.448) > naringenin
(9.206) > hesperetin (8.335) > catechin
(8.353) > luteolin (8.177) > eriodictyol (8.161)
> apigenin (8.142) > quercetin-(7.965) > kaempferol
(7.954) > theaflavin (7.918) > isorhamnetin (7.742)
(Table 8). The docking scores and drug-likeness scores
imply that these flavonoids are suitable alternative anti-
microbial agents, which could be used as complementary/
supplementary agents, for controlling drug-resistant
bacterial strains.In the advanced drug discovery process, the Lipinski rules
of five (RO5) or Pfizer’s rule of five are considered to have
important roles in the selection of a possible drug candidate/
lead compound.33 According to the RO5, a chemical/drug
candidate would be ideal when it has a molecular weight in
the range 180e500 g/mol, has 10 or less H-bond acceptors,
has 5 or less H-bond donors, the XLogP3 (octanol/water
partition coefficients) should be between 0.4 and 5.6, and
the topological polar surface area (TPSA) should be not
more than 140 A˚2.
Two out of 11 flavonoids used, epigallocatechin 3-gallate
and theaflavin, and the antibiotic amikacin do not follow the
RO5. The criteria laid down in the RO5 are advanced con-
cepts for the selection of suitable intended agents,33
nevertheless it is not universally followed with respect to
the activity of a compound. As we have demonstrated,
amikacin and the most effective flavonoid, epigallocatechin
3-gallate, overrule the RO5. Thus, flavonoids used in this
study could be promoted as new antibacterials against
ESBL.Conclusions
The present work describes the relationships of 9 types of
ESBL enzymes that were ascertained through the con-
structed phylogenetic tree, using multiple sequence align-
ments of protein sequences of ESBL variants. Stable
configurations and validations of the 9 ESBL protein struc-
tures were modelled and analysed with several tools, such as
SAVES (PROCKECK, ERRAT, Verify), as well as WHAT
IF, MolProbity and ProSA. It was evident that the structures
generated were geometrically and stereochemically accept-
able. For example, 97.5% of residues of the A. baumannii
TEM-1 were in the most favoured regions, while the
remaining 2.5% residues were in additional allowed regions.
No residues fell in the disallowed regions. Here, the ESBL
structures generated were aptly druggable candidates as
targets for future study, including identification of suitable
inhibitor(s) for ESBLs. The 3-D structures of 9 ESBLs have
not been reported in PDB; these models may be used in drug
discovery efforts in the future. Moreover, these 11 flavonoids
Table 7: Information and 3-D structure of 11 flavonoids and an antibiotic.
Flavonoids Information 3D-structure Drug-likeness score
Apigenin MF: C15H10O5
MW: 270.2369 g/mol
H-bd: 3
H-ba: 5
XLogP3: 1.7
TPSA: 87
0.77
Catechin MF: C15H14O6
MW: 290.26806 g/mol
H-bd: 5
H-ba: 6
XLogP3:0.4
TPSA: 110
0.92
Epigallocatechin 3-gallate MF: 458.37172 g/mol
MW: C22H18O11 g/mol
H-bd: 8
H-ba: 11
XLogP3: 1.2
TPSA: 197
0.39
Eriodictyol MF: C15H12O6
MW: 288.25218 g/mol
H-bd: 4
H-ba: 6
XLogP3:1
TPSA: 107
1.37
Hesperetin MF: C16H14O6
MW: 302.27876 g/mol
H-bd: 3
H-ba: 6
XLogP3: 2.4
TPSA: 96.2
0.88
Isorhamnetin MF: C16H12O7
MW: 316.26228 g/mol
H-bd: 4
H-ba: 7
XLogP3: 1.9
TPSA: 116
0.67
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Table 7 (continued )
Flavonoids Information 3D-structure Drug-likeness score
Kaempferol MF: C15H10O6
MW: 286.2363 g/mol
H-bd: 4
H-ba: 6
XLogP3: 1.9
TPSA: 107
0.77
Luteolin MF: C15H10O6
MW: 286.2363 g/mol
H-bd: 4
H-ba: 6
XLogP3: 1.4
TPSA: 107
0.86
Naringenin MF: C15H12O5
MW: 272.25278 g/mol
H-bd: 3
H-ba: 5
XLogP3: 2.4
TPSA: 87
1.13
Quercetin MF: C15H10O7
MW: 302.2357 g/mol
H-bd: 5
H-ba: 7
XLogP3: 1.5
TPSA: 127
0.93
Theaflavin MF: C29H24O12
MW: 564.49366 g/mol
H-bd: 9
H-ba: 12
XLogP3: 0.6
TPSA: 218
0.31
Amikacina MF: C22H43N5O13
MW: 585.60252 g/mol
H-bd: 13
H-ba: 17
XLogP3: 7.9
TPSA: 332
1.03
a Antibiotic; H-bc, H-bond acceptor; H-bd, h-bond donor; mf, molecular formula; mw, molecular weight; TPSA, topological polar
surface area.
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Table 8: Docking scores of 11 flavonoids and an antibiotic
against 2 ESBL target proteins.
Flavonoids Docking score values (kcal/mol)
A. baumannii
(TEM-1 wild,
generated model
by homology
modelling)
E. coli
(TEM-1 mutant,
retrieved model,
PDB ID: 1ESU)
Apigenin 8.245 8.142
Catechin 8.870 8.353
Epigallocatechin
3-gallate
9.665 9.448
Eriodictyol 8.432 8.161
Hesperetin 8.456 8.335
Isorhamnetin 7.809 7.742
Kaempferol 8.219 7.954
Luteolin 8.226 8.177
Naringenin 9.658 9.206
Quercetin 8.209 7.965
Theaflavin 7.989 7.918
Amikacina 8.108 7.388
a Antibiotic.
S.S. Swain and R.N. Padhy228are predicted to be effective as inhibitors of ESBLs, with
epigallocatechin 3-gallate and eriodictyol being the most
suitable agents based on both docking and drug-likeness
scores.
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